Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Oncology and Therapy
Published in: Oncology and Therapy 2/2018

Open Access 01-12-2018 | Commentary

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria

Authors: Andrea Lanese, Enrico Franceschi, Alba A. Brandes

Published in: Oncology and Therapy | Issue 2/2018

Login to get access

Abstract

Diffuse low-grade gliomas (LGG) are rare tumors that affect young adult patients. The European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) have both developed their own clinical prognostic scores to assist clinicians in treatment decision-making. These criteria have been used to include patients in phase III studies. To date, it is unknown which is the best score to define the prognosis of LGG. Additionally, a pure clinical classification is probably not a sufficiently informative basis for choosing the proper treatment in different situations. A combined score with both clinical and molecular features will likely be indispensable.
Literature
1.
Rees J, Watt H, Jäger HR, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72(1):54–64.CrossRef
2.
Sahm F, Capper D, Jeibmann A, et al. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69(4):523–6.CrossRef
3.
Pouratian N, Asthagiri A, Jagannathan J, et al. Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007;3:628–39.CrossRef
4.
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRef
5.
Coons SW, Johnson PC, Scheithauer BW et al. Improving diagnostic accurancy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381–93.CrossRef
6.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRef
7.
Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–84.CrossRef
8.
Karim ABMF, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.CrossRef
9.
Karim ABMF, Afra D, Cornu P. Randomized trial of the efficacy of radiotherapy for low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316–24.CrossRef
10.
Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41.CrossRef
11.
Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55.CrossRef
12.
Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a restrospective study in 379 patients. J Clin Oncol. 1997;15:3129–40.
13.
Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and the timing of radiation. J Clin Oncol. 1997;15:1294–301.CrossRef
14.
Smith JS, Chang EF, Lamborn KR et al. Role of extent of resection in the long term outcome of low-grade hemispheric glioma. J Clin Oncol. 2008;26:1338–45.CrossRef
15.
Shibamoto Y, Kitakabu Y, Takahashi M et al. Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 1993;72(1):190–5.CrossRef
16.
Baumert BG, Hegi ME, van den Bent MJ et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–32.CrossRef
17.
Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103–12.CrossRef
Metadata
Title
The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria
Authors
Andrea Lanese
Enrico Franceschi
Alba A. Brandes
Publication date
01-12-2018
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 2/2018
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-018-0063-9

Other articles of this Issue 2/2018

Oncology and Therapy 2/2018 Go to the issue

Review

Mastocytosis: One Word for Different Diseases

Original Research

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases

Original Research

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Review

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

Original Research

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Review

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits